Screener
Haemonetics HAE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 27,111 | 28,758 |
| Amortization of fair value inventory step-up | — | 2,436 |
| Share-based compensation expense | 9,311 | 9,312 |
| Deferred income taxes | 668 | (3,231) |
| Other non-cash operating activities | 2,227 | 1,571 |
| Change in operating assets and liabilities: | ||
| Change in accounts receivable | 297 | 3,557 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's stock-based comp?
- Haemonetics (HAE) reported stock-based comp of $9.31M in Q2 2026.
- How has Haemonetics's stock-based comp changed year-over-year?
- Haemonetics's stock-based comp decreased by 0.0% year-over-year, from $9.31M to $9.31M.
- What is the long-term trend for Haemonetics's stock-based comp?
- Over 4 years (2022 to 2026), Haemonetics's stock-based comp has grown at a 8.6% compound annual growth rate (CAGR), from $24.36M to $33.83M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Haemonetics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude